Cargando…

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study

Objective To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Design Self controlled case series analysis. Setting Nationwide health insurance database, 1 January 2008 to 31 D...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Ju-Young, Roughead, Elizabeth E, Park, Byung-Joo, Pratt, Nicole L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887614/
https://www.ncbi.nlm.nih.gov/pubmed/27245699
http://dx.doi.org/10.1136/bmj.i2550
_version_ 1782434753769635840
author Shin, Ju-Young
Roughead, Elizabeth E
Park, Byung-Joo
Pratt, Nicole L
author_facet Shin, Ju-Young
Roughead, Elizabeth E
Park, Byung-Joo
Pratt, Nicole L
author_sort Shin, Ju-Young
collection PubMed
description Objective To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Design Self controlled case series analysis. Setting Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. Participants 1224 patients aged ≤17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. Main outcome measures A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. Results Increased risk of arrhythmia was observed in all exposed time periods—that is, periods of treatment with methylphenidate—(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. Conclusion The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
format Online
Article
Text
id pubmed-4887614
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-48876142016-06-01 Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study Shin, Ju-Young Roughead, Elizabeth E Park, Byung-Joo Pratt, Nicole L BMJ Research Objective To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Design Self controlled case series analysis. Setting Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. Participants 1224 patients aged ≤17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. Main outcome measures A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. Results Increased risk of arrhythmia was observed in all exposed time periods—that is, periods of treatment with methylphenidate—(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. Conclusion The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD. BMJ Publishing Group Ltd. 2016-05-31 /pmc/articles/PMC4887614/ /pubmed/27245699 http://dx.doi.org/10.1136/bmj.i2550 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
spellingShingle Research
Shin, Ju-Young
Roughead, Elizabeth E
Park, Byung-Joo
Pratt, Nicole L
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
title Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
title_full Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
title_fullStr Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
title_full_unstemmed Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
title_short Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
title_sort cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (adhd): nationwide self controlled case series study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887614/
https://www.ncbi.nlm.nih.gov/pubmed/27245699
http://dx.doi.org/10.1136/bmj.i2550
work_keys_str_mv AT shinjuyoung cardiovascularsafetyofmethylphenidateamongchildrenandyoungpeoplewithattentiondeficithyperactivitydisorderadhdnationwideselfcontrolledcaseseriesstudy
AT rougheadelizabethe cardiovascularsafetyofmethylphenidateamongchildrenandyoungpeoplewithattentiondeficithyperactivitydisorderadhdnationwideselfcontrolledcaseseriesstudy
AT parkbyungjoo cardiovascularsafetyofmethylphenidateamongchildrenandyoungpeoplewithattentiondeficithyperactivitydisorderadhdnationwideselfcontrolledcaseseriesstudy
AT prattnicolel cardiovascularsafetyofmethylphenidateamongchildrenandyoungpeoplewithattentiondeficithyperactivitydisorderadhdnationwideselfcontrolledcaseseriesstudy